SpineVision raises $5M

Paris-based SpineVision has raised $5 million and will use the money to accelerate market penetration of its next-generation devices for spinal treatment. The funds come from Partner Capital, Sofinnova, BroadPeak, HealthCap, Innoven, Edbi and other individuals.

"We now have a focused and streamlined international operation that is steadfastly penetrating the market for minimally invasive and motion-preservation spinal therapies," says Gérard Hascoët, chairman and CEO of SpineVision, in a statement. "Flex+ is an ingenious dynamic-stabilization system that offers multiple stabilizing options in concert with our equally innovative minimally invasive screw system, LUMIS."

Flex+ Hybrid uses technology that enables the combination of rigid and flexible parts in one low-profile implant. "As such, Flex+ used in combination with LUMIS is a unique solution allowing to preempt pathologies at adjacent levels by protecting the adjacent discs, and to improve patient outcome by reducing the need for a large incision," explains Arnaud Brisard, COO of SpineVision.

As the company notes on its website, new market opportunities and the quality of its current product lines is allowing SpineVision to focus its R&D efforts on motion preservation and minimally invasive technologies.

- see the SpineVision statement

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.